srch

Related Pharma Letter News · Pieris out-licenses PRS-342 for up to $365 million · GSK in out-licensing deal with Boston Pharmaceuticals · Boston Pharma nabs former ...

Boston Pharmaceuticals announced today a pioneering three-year out-license and option agreement with GlaxoSmithKline PLC (LSE/NYSE: GSK).

Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for …

Zealand Pharma announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to ...

08.12.2021 · BOSTON, Dec. 8, 2021 /PRNewswire/ -- Humans are the linchpin of healthcare industry and the scientific improvements encouraging it: this is the firm belief that BIOVISER, a Boston -based pharma...

The Boston Business Journal features local business news about Boston. We also provide tools to help businesses grow, network and hire.

Mar 18, 2021 · Boston Pharmaceuticals is a clinical stage biopharmaceutical company that leverages an experienced drug development team to advance a portfolio of high value candidates that address important ...

12-19-19 - Boston Pharmaceuticals Appoints Joanne Beck, PhD, as Chief Operating Officer.

Scroll. NEWS & EVENTS. Press Releases. 10/4/2021. 4/26/2021. Boston Pharmaceuticals Doses First Patient in Phase 2a Clinical Trial of BOS-580 for NASH. Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific. 3/18/2021.

Boston Pharmaceuticals and GlaxoSmithKline have entered into a three-year out-license and option agreement for pre-phase two programmes.

23.12.2021 · The Boston Business Journal features local business news about Boston. We also provide tools to help businesses grow, network and hire.

23.12.2021 · The Boston Business Journal features local business news about Boston. We also provide tools to help businesses grow, network and hire.

The post Boston initiates Phase IIa trial of drug candidate for NASH appeared first on Clinical Trial... See more ». Boston Pharmaceuticals's News Image.

Waypoint Capital Acquires Majority Stake in Allergy Partners · Boston Pharmaceuticals Signs Pioneering Out-License Agreement With GSK · Waypoint ...

Dec 08, 2021 · BOSTON, Dec. 8, 2021 /PRNewswire/ -- Humans are the linchpin of healthcare industry and the scientific improvements encouraging it: this is the firm belief that BIOVISER, a Boston -based pharma...

Boston Pharmaceuticals. Pharmaceutical Manufacturing. Cambridge, MA 3,513 followers. Transforming the right molecules into the best medicines™. See jobs Follow.

18.03.2021 · Boston Pharmaceuticals announced today a pioneering three-year out-license and option agreement with GlaxoSmithKline PLC (LSE/NYSE: GSK). Boston Pharm

Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.

17.12.2021 · Opioid Crisis Purdue Bankruptcy Jen Trejo from California holds a sign that reads "SACKLERS KILLED MY SON" during a protest with other advocates for opioid victims outside the Department of Justice, Friday, Dec. 3, 2021, in Washington. Trejo's son Christopher was 32 when he died. A federal judge has rejected OxyContin maker Purdue Pharma’s sweeping deal to …

08.12.2021 · Pharma Bro Lawsuit FILE- Pharmaceutical chief Martin Shkreli speaks on Capitol Hill in Washington, on Feb. 4, 2016, during the House Committee on Oversight and Reform Committee hearing on his former company's decision to raise the price of a lifesaving medicine. Vyera Pharmaceuticals, a company once owned by Shkreli, will pay up to $40 million to settle …

19.03.2021 · News Boston Pharma signs out-licensing agreement with GSK 19 Mar 2021 (Last Updated November 2nd, 2021 06:57) Boston Pharmaceuticals and GlaxoSmithKline (GSK) have entered into a three-year out-license and option agreement to …

Dec 23, 2021 · Ranked by Number of SBA 7(A) Loans Originated Between Oct. 1, 2020 and Sept. 30, 2021 Ranked by Massachusetts deposits as of June 30, 2021 Bernie and Lorraine Horn both contracted COVID-19 in the ...

08.12.2021 · A company once owned by “Pharma Bro" Martin Shkreli will pay up to $40 million to settle allegations that it jacked up the price of a life-saving medication by roughly 4,000% after obtaining exclusive rights to the drug, the Federal Trade Commission announced Tuesday. The FTC said Vyera Pharmaceuticals LLC and its parent company, Phoenixus AG ...

Dec 23, 2021 · Boston's lab buildings face uphill climb to meet new emissions requirements Dec 15, 2021, 6:30 am EST Mythic Therapeutics targets cancer with new $103M investment

Scroll. NEWS & EVENTS. Press Releases. 10/4/2021. 4/26/2021. Boston Pharmaceuticals Doses First Patient in Phase 2a Clinical Trial of BOS-580 for NASH. Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific. 3/18/2021.